A Phase I/II Clinical Trial to Evaluate the Safety and Clinical Activity of IDEC-Y2B8 Administered to Patients with B-Cell Lymphoma (IDEC-Y2B8 Protocol Number 106-03)

Project: Research project

Project Details

StatusFinished
Effective start/end date7/17/961/1/11

Funding

  • IDEC Pharmaceuticals Corporation (106-03)